Surgery Partners (SGRY) Insider Sales: 25,000 Shares Filed on Form 144

Rhea-AI Filing Summary

Surgery Partners, Inc. insider sale notice (Form 144) reports that 25,000 shares of common stock will be offered for sale through UBS Financial Services with an aggregate market value of $562,000, representing a small fraction of the company's ~128.2 million shares outstanding. The shares were acquired and the sale was effected on 09/02/2025 through equity option exercise. Recent related transactions by the same person, Wayne DeVeydt, show sales of 100,000, 25,000 and 11,865 shares on 08/21/2025, 08/26/2025 and 08/27/2025, generating gross proceeds of $2,299,011; $572,717; and $271,756 respectively. The filer affirms no undisclosed material adverse information.

Positive

• Disclosure is detailed and compliant with Rule 144 requirements, including broker, quantities, acquisition dates, and nature of acquisition.
• Sales originated from equity compensation/exercise, indicating liquidity needs rather than transfer from external parties.

Negative

• Substantial insider selling aggregated to 136,865 shares in late August and early September, generating about $3.4 million in gross proceeds, which may concern some investors.
• Concentration of sales by a single insider (Wayne DeVeydt) over a short period could be interpreted as negative signaling despite being from exercised options.

Insights

Securities Analyst

TL;DR: Insider reported routine post-exercise sales; disclosure is material but appears procedural.

The Form 144 shows an insider offering 25,000 shares via UBS after acquiring them through an equity option exercise the same day. Aggregated with several large sales in late August totaling 136,865 shares, these disposals generated roughly $3.4 million in gross proceeds. For investors, the filing is materially relevant as it signals insider liquidity, but the transactions appear to stem from option vesting/exercise rather than company-specific negative developments. The notice includes standard attestation of no undisclosed material adverse information.

Corporate Governance Expert

TL;DR: Governance disclosure requirements were met; multiple sales warrant monitoring but not necessarily negative.

The filing identifies UBS as the executing broker and provides required details: acquisition date, nature of acquisition (equity compensation), and sale timing. Multiple recent sales by the same individual are transparent and consistent with compliance obligations under Rule 144. While concentrated insider selling can be noteworthy for governance and signaling, the document contains no statement of undisclosed adverse information and does not itself indicate wrongdoing or regulatory issues.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	25000	562000	128209410	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/02/2025	Equity Compensation	Surgery Partners, Inc.			25000	09/02/2025	Equity Option Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Surgery Partners (SGRY) Form 144 filed on 09/02/2025 disclose?

The notice discloses an intended sale of 25,000 common shares via UBS with an aggregate market value of $562,000; the shares were acquired on 09/02/2025 through an equity option exercise.

Who conducted recent share sales for SGRY and how many shares were sold?

Wayne DeVeydt sold 100,000, 25,000, and 11,865 shares on 08/21/2025, 08/26/2025, and 08/27/2025 respectively.

How much gross proceeds did the recent insider sales generate?

The reported gross proceeds were approximately $2,299,011, $572,717, and $271,756 for the three August sales listed.

Are the shares being sold a large portion of outstanding stock?

No; the 25,000 shares represent a small fraction of the reported 128,209,410 shares outstanding.

Were the shares sold part of compensation or a gift?

The Form 144 states the shares were acquired via equity compensation and sold following an equity option exercise.